샘플 요청 목록

 카트 문의
시장보고서
상품코드
1584105

클로스트리듐 디피실 감염증 치료 시장 : 제품 유형별, 투여 경로별, 유통경로별, 국가별, 지역별 - 산업 분석, 시장 규모, 시장 점유율, 예측(2024-2032년)

Clostridioides Difficile Infection Treatment Market, By Product Type, By Route of Administration, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
발행일: | 리서치사: AnalystView Market Insights | 페이지 정보: 영문 316 Pages | 배송안내 : 2-3일 (영업일 기준)

    
    
    




※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

리포트 하이라이트

클로스트리듐 디피실 감염증 치료 시장 규모는 2023년에 8억 1,021만 달러에 달하며, 2024-2032년 CAGR 6.10%로 확대

클로스트리듐 디피실 감염증 치료 시장 - 시장 역학

감염증의 만연과 신규 치료법의 개발이 시장 수요를 촉진

크로스트리듐 디피실 감염 치료제 시장은 감염 유병률 증가와 새로운 치료법 개발로 인해 급격한 변화를 겪고 있습니다. 클로스트리듐 디피실 감염은 의료 환경 및 항생제 사용과 관련이 있는 경우가 많아 전 세계 의료 시스템에 큰 부담을 주고 있으며, 이는 첨단이고 효과적인 치료 옵션의 필요성을 강조하고 있습니다. 여러 요인이 시장 역학에 영향을 미치고 있으며, 이러한 감염증 증가는 의료계에 큰 도전이 되고 있습니다. 입원 기간이 길어지고, 광범위 항생제 사용과 고령화로 인해 클로스트리듐 디피실 감염에 대한 개인의 감수성이 높아지면서 혁신적이고 효과적인 치료법에 대한 수요가 증가하고 있습니다. 기술의 발전은 치료의 전망을 바꾸고 있으며, 항균제, 분변 미생물총 이식(FMT), 단클론 항체 등 새로운 치료법이 이러한 감염에 대응하는 데 중요한 역할을 하고 있습니다. 또한 환자별 감염 프로파일에 기반한 표적 치료를 통한 정밀의료의 통합은 보다 개인화되고 효과적인 치료 전략에 기여하고 있습니다.

클로스트리디움 디피실 감염 치료제 시장 - 주요 인사이트

당사의 리서치 애널리스트가 공유한 분석에 따르면 세계 시장은 예측 기간(2024-2032년) 동안 매년 약 6.10%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예상됩니다.

투여 경로별로는 경구제가 2023년에 가장 높은 시장 점유율을 보였습니다.

유통 채널별로는 2023년 병원 약국이 주요 유형으로 부상할 것으로 예상됩니다.

지역별로는 북미가 2023년 주요 수입원으로 부상했습니다.

클로스트리듐 디피실 감염증 치료제 시장 - 세분화 분석 :

세계 클로스트리듐 디피실 감염증 치료제 시장은 제품 유형, 투여 경로, 유통 채널 및 지역에 따라 세분화됩니다.

시장은 투여 경로에 따라 경구제와 주사제의 두 가지 범주로 나뉘며, 2023년에도 경구 투여 경로는 환자에게 편리하고 접근하기 쉽기 때문에 가장 일반적입니다. 메트로니다졸, 반코마이신, 피닥소마이신과 같은 항생제의 경구 투여는 외래 치료를 지원하고 특히 중증도가 낮은 경우 환자의 순응도를 향상시킵니다. 그러나 중증 및 복잡한 경우에는 항생제 주사제를 사용합니다.

시장은 유통 채널에 따라 병원 약국, 소매 약국, 통신판매 약국 등 세 가지 범주로 나뉘며, 2023년에는 병원 약국이 시장을 독점할 것으로 예상됩니다. 특히 중증 환자의 경우 입원 치료가 필요하므로 병원 약국은 중요한 역할을 합니다. 병원은 이러한 감염성 질환의 1차 치료 센터로서 치료제물의 유통과 투여의 중심적인 역할을 담당하고 있습니다.

클로스트리듐 디피실 감염증 치료제 시장 - 지역적 인사이트

이 시장은 지역적 경계를 넘어 북미, 라틴아메리카, 유럽, 아시아태평양, 중동 및 아프리카에서 존재감을 드러내고 있습니다. 북미는 2024년 시장 점유율이 크고 시장 관계자들이 새로운 치료법을 도입하기 위해 연구개발 활동에 집중하고 있으며, 예측 기간 중 클로스트리듐 디피실 감염증 치료제 시장을 장악할 것으로 예상됩니다. 예를 들어 2022년 9월 생명공학 기업 Seres Therapeutics, Inc.는 미국 식품의약국(FDA)에 클로스트리듐 디피실 감염 재발을 예방하기 위한 SER-109에 대한 생물학적 제제 승인 신청(BLA)을 제출했다고 발표했습니다. 완료했습니다. SER-109의 미국 시장 출시는 이러한 우위를 점하는 데 기여할 것으로 예상됩니다.

클로스트리디움 디피실 감염증 치료제 시장 - 경쟁 구도:

난치성 클로스트리듐 디피실 감염증 치료제 시장의 각 업체들은 자사의 입지를 구축하고 확대하기 위해 다양한 전략을 수립하고 있습니다. 특히 표준 항생제가 듣지 않는 재발성 CDI에 대한 혁신적인 치료법을 개발하기 위한 연구개발에 집중하고 있습니다. 임상시험을 수행하고 제품의 효능을 입증할 수 있는 실제 데이터를 수집하기 위해서는 의료진 및 의료기관과의 협력이 필수적입니다. 헬스케어는 의료진에게 최신 치료 옵션과 가이드라인에 대해 교육하는 데 중점을 두고 있습니다. 또한 기업은 종종 지불자와 전략적 파트너십을 맺어 새로운 치료법에 대한 상환을 보장함으로써 규제 문제를 효과적으로 해결하고 환자 접근성을 향상시키는 데 도움을 주고 있습니다.

목차

제1장 클로스트리듐 디피실 감염증 치료 시장 개요

  • 조사 범위
  • 시장 추정년

제2장 개요

  • 시장 내역
  • 경쟁 인사이트

제3장 클로스트리듐 디피실 감염증 치료의 주요 시장 동향

  • 시장 성장 촉진요인
  • 시장 성장 억제요인
  • 시장 기회
  • 시장의 향후 동향

제4장 클로스트리듐 디피실 감염증 치료 산업 연구

  • PEST 분석
  • Porter's Five Forces 분석
  • 성장 전망 지도제작
  • 규제 구조 분석

제5장 클로스트리듐 디피실 감염증 치료 시장 : COVID-19의 영향 분석

  • COVID-19 이전의 영향 분석
  • COVID-19 이후의 영향 분석

제6장 클로스트리듐 디피실 감염증 치료 시장 구도

  • 클로스트리듐 디피실 감염증 치료 시장 점유율 분석, 2023년
  • 주요 제조업체별 내역 데이터
    • 기존 기업의 분석
    • 신규 기업의 분석

제7장 클로스트리듐 디피실 감염증 치료 시장 - 제품 유형별

  • 개요
    • 제품 유형별 부문 점유율 분석
    • Metronidazole
    • Vancomycin
    • Fidaxomicin

제8장 클로스트리듐 디피실 감염증 치료 시장 - 투여 경로별

  • 개요
    • 투여 경로별 부문 점유율 분석
    • 경구
    • 주사제

제9장 클로스트리듐 디피실 감염증 치료 시장 - 유통 채널별

  • 개요
    • 유통 채널별 부문 점유율 분석
    • 병원 약국
    • 소매 약국
    • 통신 판매 약국

제10장 클로스트리듐 디피실 감염증 치료 시장 - 지역

  • 서론
  • 북미
    • 개요
    • 북미의 주요 제조업체
    • 미국
    • 캐나다
  • 유럽
    • 개요
    • 유럽의 주요 제조업체
    • 독일
    • 이탈리아
    • 영국
    • 프랑스
    • 러시아
    • 네덜란드
    • 스웨덴
    • 폴란드
    • 기타
  • 아시아태평양(APAC)
    • 개요
    • 아시아태평양의 주요 제조업체
    • 인도
    • 중국
    • 일본
    • 한국
    • 호주
    • 태국
    • 인도네시아
    • 필리핀
    • 기타
  • 라틴아메리카
    • 개요
    • 라틴아메리카의 주요 제조업체
    • 브라질
    • 멕시코
    • 아르헨티나
    • 콜롬비아
    • 기타
  • 중동 및 아프리카
    • 개요
    • 중동 및 아프리카의 주요 제조업체
    • 사우디아라비아
    • 아랍에미리트
    • 이스라엘
    • 터키
    • 알제리
    • 이집트
    • 기타

제11장 주요 벤더 분석 - 클로스트리듐 디피실 감염증 치료 업계

  • 경쟁 대시보드
  • 기업 개요
    • Novartis
    • Mylan NV
    • Akorn
    • Teva Pharmaceutical Industries Ltd.
    • AstraZeneca
    • Apotex Inc.
    • AbbVie Inc.
    • Pfizer Inc.
    • Strides Pharma Science Limited
    • Sanofi
    • Ferring Pharmaceuticals
    • Sun Pharmaceutical Industries Ltd.
    • Merck &Co., Inc.
    • B. Braun Medical Inc.
    • Eli Lilly and Company
    • Actelion Pharmaceuticals Ltd.
    • Astellas Pharma
    • Perrigo Pharmaceutical.
    • Hikma Pharmaceutical PLC
    • Fresenius Kabi USA
    • Others

제12장 애널리스트의 전방위 전망

KSA 24.11.14

REPORT HIGHLIGHT

Clostridioides Difficile Infection Treatment Market size was valued at USD 810.21 Million in 2023, expanding at a CAGR of 6.10% from 2024 to 2032.

Clostridioides difficile infection (CDI) is a serious gastrointestinal condition caused by the bacterium C. difficile, often triggered by antibiotic use that disrupts the normal gut microbiome. Treatment usually involves targeted antibiotics such as fidaxomicin or vancomycin. For recurrent infections, fecal microbiota transplantation (FMT) is an emerging option that restores healthy gut bacteria. The choice of treatment depends on the patient history, infection's severity, and the likelihood of recurrence. Prompt and appropriate management is important to prevent complications and minimize the risk of transmission in healthcare environments.

Clostridioides Difficile Infection Treatment Market- Market Dynamics

Increasing prevalence of infections and ongoing development of novel treatment methods to propel market demand

The Clostridium difficile infection treatment market is undergoing drastic transformation, driven by the rising prevalence of infections and ongoing development of novel treatment methods. Frequently associated with the healthcare settings and antibiotic use, Clostridium difficile infections pose a substantial burden on global healthcare systems, highlighting a need for an advanced and effective treatment options. Several factors influence market dynamics, with the increasing incidence of these infections being a major healthcare challenge. Prolonged hospital stays, widespread use of broad-spectrum antibiotics, and an aging population have heightened individual susceptibility to Clostridium difficile infections, creating a growing demand for innovative and effective treatments. Technological advancements are reshaping the treatment landscape, with novel therapies such as antimicrobial agents, fecal microbiota transplantation (FMT), and monoclonal antibodies playing a key role in combating these infections. Additionally, the integration of precision medicine, through targeted therapies based on a patient's specific infection profile, is contributing to more personalized and effective treatment strategies.

Clostridioides Difficile Infection Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 6.10% over the forecast period (2024-2032)

Based on Route of Administration segmentation, oral was predicted to show maximum market share in the year 2023

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading type in 2023

On the basis of region, North America was the leading revenue generator in 2023

Clostridioides Difficile Infection Treatment Market- Segmentation Analysis:

The Global Clostridioides Difficile Infection Treatment Market is segmented on the basis of Product Type, Route of Administration, Distribution Channel, and Region.

The market is divided into two categories based on Route of Administration: Oral and Injectables. In 2023, the oral route remains the most common due to its convenience and accessibility for patients. Oral administration of antibiotics, such as metronidazole, vancomycin, and fidaxomicin, supports outpatient care and improves patient adherence, particularly in less severe cases. However, in severe or complicated cases, injectable antibiotic formulations are utilized.

The market is divided into three categories based on Distribution Channel: Hospital Pharmacies, Retail Pharmacies and Mail-Order Pharmacies. Hospital pharmacies are expected to dominate the market in 2023. Hospital pharmacies play a key role, particularly given the need for inpatient care in severe cases. As primary treatment centers for these infections, hospitals are central to the distribution and administration of therapeutic agents.

Clostridioides Difficile Infection Treatment Market- Geographical Insights

This market transcends geographical boundaries, with a presence in North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America is projected to dominate the Clostridioides difficile infection treatment market during the forecast period, driven by the region's significant market share in 2024 and the focus of market players on research and development activities to introduce new therapies. For example, in September 2022, Seres Therapeutics, Inc., a biotechnology company, announced the completion of its rolling Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for SER-109, aimed at preventing recurrent Clostridioides difficile infection. The introduction of SER-109 in the U.S. market is expected to contribute to this dominance.

Clostridioides Difficile Infection Treatment Market- Competitive Landscape:

Companies in the CDI treatment market devising various strategies to establish and expand their presence. A major emphasis is placed on research and development to create innovative therapies, especially for recurrent CDI, where standard antibiotics may be ineffective. Collaborations with healthcare providers and institutions are crucial for conducting clinical trials and gathering real-world data to demonstrate product efficacy. Marketing efforts focus on educating healthcare professionals about the latest treatment options and guidelines. Additionally, companies often form strategic partnerships with payers to secure reimbursement for new therapies, improving patient access while effectively addressing regulatory challenges.

Recent Developments:

In October 2022, Acurx Pharmaceuticals, Inc., a leading bioProduct Type company, made notable contributions to the field of infectious diseases by presenting both a poster and an oral presentation at the Infectious Disease Society of America (IDSA) IDWeek 2022 Conference.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHT

Novartis

Mylan N.V.

Akorn

Teva Pharmaceutical Industries Ltd.

AstraZeneca

Apotex Inc.

AbbVie Inc.

Pfizer Inc.

Strides Pharma Science Limited

Sanofi

Ferring Pharmaceuticals

Sun Pharmaceutical Industries Ltd.

Merck & Co., Inc.

B. Braun Medical Inc.

Eli Lilly and Company

Actelion Pharmaceuticals Ltd.

Astellas Pharma

Perrigo Pharmaceutical.

Hikma Pharmaceutical PLC

Fresenius Kabi USA

Others

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY PRODUCT TYPE - MARKET ANALYSIS, 2019 - 2032

  • Metronidazole
  • Vancomycin
  • Fidaxomicin

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Injectables

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Mail-Order Pharmacies

GLOBAL CLOSTRIDIOIDES DIFFICILE INFECTION TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Clostridioides Difficile Infection Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Clostridioides Difficile Infection Treatment Market Snippet by Product Type
    • 2.1.2. Clostridioides Difficile Infection Treatment Market Snippet by Route of Administration
    • 2.1.3. Clostridioides Difficile Infection Treatment Market Snippet by Distribution Channel
    • 2.1.4. Clostridioides Difficile Infection Treatment Market Snippet by Country
    • 2.1.5. Clostridioides Difficile Infection Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Clostridioides Difficile Infection Treatment Key Market Trends

  • 3.1. Clostridioides Difficile Infection Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Clostridioides Difficile Infection Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Clostridioides Difficile Infection Treatment Market Opportunities
  • 3.4. Clostridioides Difficile Infection Treatment Market Future Trends

4. Clostridioides Difficile Infection Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Clostridioides Difficile Infection Treatment Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Clostridioides Difficile Infection Treatment Market Landscape

  • 6.1. Clostridioides Difficile Infection Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Clostridioides Difficile Infection Treatment Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2023 & 2032 (%)
    • 7.1.2. Metronidazole
    • 7.1.3. Vancomycin
    • 7.1.4. Fidaxomicin

8. Clostridioides Difficile Infection Treatment Market - By Route of Administration

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 8.1.2. Oral
    • 8.1.3. Injectables

9. Clostridioides Difficile Infection Treatment Market - By Distribution Channel

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 9.1.2. Hospital Pharmacies
    • 9.1.3. Retail Pharmacies
    • 9.1.4. Mail-Order Pharmacies

10. Clostridioides Difficile Infection Treatment Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Clostridioides Difficile Infection Treatment Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.8. Italy
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.8.4. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.8.5. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.9. United Kingdom
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. United Kingdom Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.9.4. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.9.5. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.10. France
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.10.4. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.10.5. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.11. Russia
      • 10.3.11.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.2. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.11.3. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.11.4. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.12. Netherlands
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.13. Sweden
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.14. Poland
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.3.15. Rest of Europe
      • 10.3.15.1. Overview
      • 10.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.3.15.5. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.9. Japan
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.9.4. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.9.5. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.10. South Korea
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.10.4. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.10.5. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Clostridioides Difficile Infection Treatment Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Clostridioides Difficile Infection Treatment Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Novartis
    • 11.2.2. Mylan N.V.
    • 11.2.3. Akorn
    • 11.2.4. Teva Pharmaceutical Industries Ltd.
    • 11.2.5. AstraZeneca
    • 11.2.6. Apotex Inc.
    • 11.2.7. AbbVie Inc.
    • 11.2.8. Pfizer Inc.
    • 11.2.9. Strides Pharma Science Limited
    • 11.2.10. Sanofi
    • 11.2.11. Ferring Pharmaceuticals
    • 11.2.12. Sun Pharmaceutical Industries Ltd.
    • 11.2.13. Merck & Co., Inc.
    • 11.2.14. B. Braun Medical Inc.
    • 11.2.15. Eli Lilly and Company
    • 11.2.16. Actelion Pharmaceuticals Ltd.
    • 11.2.17. Astellas Pharma
    • 11.2.18. Perrigo Pharmaceutical.
    • 11.2.19. Hikma Pharmaceutical PLC
    • 11.2.20. Fresenius Kabi USA
    • 11.2.21. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us
샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제